[Asia Economy Reporter Lee Gwan-joo] Curatis announced on the 8th that it has submitted an application for preliminary review for listing on the KOSDAQ market to the Korea Exchange.
Curatis is a global vaccine specialist company currently developing a new tuberculosis vaccine drug (QTP101) for adolescents and adults, as well as a next-generation mRNA COVID-19 vaccine (QTP104).
This application comes about five months after passing the technology evaluation in March. Daishin Securities and ShinYoung Securities are acting as joint lead managers.
One of Curatis's main products, 'QTP101,' received approval for global Phase 2b/3 clinical trial plans from the Ministry of Food and Drug Safety on the 21st of last month. The trial will evaluate efficacy, immunogenicity, and safety in healthy adolescents and adults.
The new COVID-19 vaccine drug 'QTP104' has completed subject enrollment and administration for the domestic primary vaccination Phase 1 clinical trial, aiming to complete the trial in the second half of the year.
To prepare for product commercialization, Curatis completed the Osong Bio Plant in Chungcheongbuk-do in August 2020 and obtained GMP (Good Manufacturing Practice) certification from the Ministry of Food and Drug Safety in January this year. It provides contract manufacturing (CMO) and contract development and manufacturing (CDMO) services for domestic and international new drug development companies.
A Curatis official stated, “Using the KOSDAQ listing as a stepping stone, we will lead not only investment in the commercialization of the tuberculosis vaccine under development but also the commercialization of our main technological products and the self-sufficiency of the domestic vaccine market after listing.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
